Annual CFO
-$2.15 M
+$1.64 M+43.29%
30 April 2024
Summary:
PharmaCyte Biotech annual cash flow from operations is currently -$2.15 million, with the most recent change of +$1.64 million (+43.29%) on 30 April 2024. During the last 3 years, it has risen by +$1.18 million (+35.41%). PMCB annual CFO is now -9679.55% below its all-time high of -$22.00 thousand, reached on 30 April 2002.PMCB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$373.30 K
-$40.30 K-12.10%
31 July 2024
Summary:
PharmaCyte Biotech quarterly cash flow from operations is currently -$373.30 thousand, with the most recent change of -$40.30 thousand (-12.10%) on 31 July 2024. Over the past year, it has increased by +$1.61 million (+81.19%). PMCB quarterly CFO is now -164.22% below its all-time high of $581.30 thousand, reached on 31 January 2007.PMCB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$2.87 M
-$716.30 K-33.29%
31 July 2024
Summary:
PharmaCyte Biotech TTM cash flow from operations is currently -$2.87 million, with the most recent change of -$716.30 thousand (-33.29%) on 31 July 2024. Over the past year, it has dropped by -$396.30 thousand (-16.03%). PMCB TTM CFO is now -25736.04% below its all-time high of -$11.10 thousand, reached on 31 July 2003.PMCB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +43.3% | +81.2% | -16.0% |
| 3 y3 years | +35.4% | +73.1% | +31.0% |
| 5 y5 years | +25.2% | +36.0% | -6.8% |
PMCB Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +47.7% | -208.8% | +81.2% | -36.1% | +39.0% |
| 5 y | 5 years | at high | +47.7% | -208.8% | +81.2% | -36.1% | +39.0% |
| alltime | all time | -9679.5% | +57.6% | -164.2% | +81.2% | <-9999.0% | +43.5% |
PharmaCyte Biotech Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | -$373.30 K(+12.1%) | -$2.87 M(+33.3%) |
| Apr 2024 | -$2.15 M(-43.3%) | -$333.00 K(+88.0%) | -$2.15 M(+2.1%) |
| Jan 2024 | - | -$177.10 K(-91.1%) | -$2.11 M(-14.8%) |
| Oct 2023 | - | -$1.98 M(-678.5%) | -$2.47 M(+4.4%) |
| July 2023 | - | $343.00 K(-218.9%) | -$2.37 M(-37.6%) |
| Apr 2023 | -$3.79 M(-7.9%) | -$288.40 K(-46.8%) | -$3.79 M(-19.2%) |
| Jan 2023 | - | -$541.70 K(-71.2%) | -$4.70 M(+5.5%) |
| Oct 2022 | - | -$1.88 M(+73.3%) | -$4.45 M(+12.5%) |
| July 2022 | - | -$1.08 M(-9.0%) | -$3.96 M(-3.8%) |
| Apr 2022 | -$4.12 M(+23.6%) | -$1.19 M(+299.1%) | -$4.12 M(+6.5%) |
| Jan 2022 | - | -$298.60 K(-78.4%) | -$3.87 M(-7.0%) |
| Oct 2021 | - | -$1.39 M(+11.6%) | -$4.16 M(+3.4%) |
| July 2021 | - | -$1.24 M(+32.0%) | -$4.02 M(+20.7%) |
| Apr 2021 | -$3.33 M(+42.4%) | -$940.30 K(+59.6%) | -$3.33 M(+9.9%) |
| Jan 2021 | - | -$589.10 K(-52.9%) | -$3.03 M(+8.5%) |
| Oct 2020 | - | -$1.25 M(+127.0%) | -$2.79 M(+31.4%) |
| July 2020 | - | -$551.00 K(-13.8%) | -$2.13 M(-9.1%) |
| Apr 2020 | -$2.34 M(-18.7%) | -$639.40 K(+81.5%) | -$2.34 M(-0.9%) |
| Jan 2020 | - | -$352.20 K(-39.7%) | -$2.36 M(-12.1%) |
| Oct 2019 | - | -$583.60 K(-23.5%) | -$2.68 M(-11.1%) |
| July 2019 | - | -$763.10 K(+15.4%) | -$3.02 M(+4.9%) |
| Apr 2019 | -$2.88 M(-43.3%) | -$661.40 K(-2.2%) | -$2.88 M(-19.9%) |
| Jan 2019 | - | -$676.50 K(-26.3%) | -$3.59 M(-12.1%) |
| Oct 2018 | - | -$917.80 K(+47.5%) | -$4.09 M(-14.2%) |
| July 2018 | - | -$622.20 K(-54.7%) | -$4.77 M(-6.2%) |
| Apr 2018 | -$5.08 M(+52.1%) | -$1.37 M(+17.2%) | -$5.08 M(+12.7%) |
| Jan 2018 | - | -$1.17 M(-26.5%) | -$4.51 M(+5.8%) |
| Oct 2017 | - | -$1.60 M(+70.6%) | -$4.26 M(+26.4%) |
| July 2017 | - | -$935.60 K(+16.8%) | -$3.37 M(+0.9%) |
| Apr 2017 | -$3.34 M(-23.2%) | -$800.90 K(-13.4%) | -$3.34 M(-11.1%) |
| Jan 2017 | - | -$925.30 K(+31.0%) | -$3.76 M(-2.2%) |
| Oct 2016 | - | -$706.30 K(-22.1%) | -$3.84 M(-8.3%) |
| July 2016 | - | -$906.90 K(-25.6%) | -$4.19 M(-3.6%) |
| Apr 2016 | -$4.35 M(-4.7%) | -$1.22 M(+20.5%) | -$4.35 M(+3.0%) |
| Jan 2016 | - | -$1.01 M(-4.0%) | -$4.22 M(-1.3%) |
| Oct 2015 | - | -$1.05 M(-1.0%) | -$4.27 M(-11.7%) |
| July 2015 | - | -$1.06 M(-2.6%) | -$4.84 M(+6.1%) |
| Apr 2015 | -$4.56 M(+193.3%) | -$1.09 M(+2.5%) | -$4.56 M(+3.5%) |
| Jan 2015 | - | -$1.07 M(-34.1%) | -$4.41 M(+22.7%) |
| Oct 2014 | - | -$1.62 M(+105.5%) | -$3.59 M(+64.6%) |
| July 2014 | - | -$786.80 K(-16.1%) | -$2.18 M(+40.3%) |
| Apr 2014 | -$1.55 M | -$938.20 K(+275.7%) | -$1.55 M(+104.7%) |
| Jan 2014 | - | -$249.70 K(+20.6%) | -$759.50 K(+29.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2013 | - | -$207.10 K(+29.7%) | -$587.40 K(+26.4%) |
| July 2013 | - | -$159.70 K(+11.7%) | -$464.80 K(+19.0%) |
| Apr 2013 | -$390.40 K(+50.6%) | -$143.00 K(+84.3%) | -$390.50 K(+30.4%) |
| Jan 2013 | - | -$77.60 K(-8.2%) | -$299.50 K(+16.1%) |
| Oct 2012 | - | -$84.50 K(-1.1%) | -$258.00 K(+14.6%) |
| July 2012 | - | -$85.40 K(+64.2%) | -$225.10 K(-13.2%) |
| Apr 2012 | -$259.30 K(+15.1%) | -$52.00 K(+44.0%) | -$259.30 K(-25.7%) |
| Jan 2012 | - | -$36.10 K(-30.0%) | -$349.20 K(-8.6%) |
| Oct 2011 | - | -$51.60 K(-56.9%) | -$382.00 K(+15.2%) |
| July 2011 | - | -$119.60 K(-15.7%) | -$331.70 K(+47.2%) |
| Apr 2011 | -$225.20 K(-76.9%) | -$141.90 K(+106.0%) | -$225.30 K(+65.3%) |
| Jan 2011 | - | -$68.90 K(+5200.0%) | -$136.30 K(-16.8%) |
| Oct 2010 | - | -$1300.00(-90.2%) | -$163.90 K(-62.6%) |
| July 2010 | - | -$13.20 K(-75.0%) | -$438.70 K(-55.0%) |
| Apr 2010 | -$974.10 K(-17.8%) | -$52.90 K(-45.2%) | -$974.00 K(-37.8%) |
| Jan 2010 | - | -$96.50 K(-65.0%) | -$1.57 M(-8.4%) |
| Oct 2009 | - | -$276.10 K(-49.7%) | -$1.71 M(+9.2%) |
| July 2009 | - | -$548.50 K(-15.0%) | -$1.57 M(+32.1%) |
| Apr 2009 | -$1.19 M(-0.5%) | -$645.20 K(+167.8%) | -$1.19 M(+79.4%) |
| Jan 2009 | - | -$240.90 K(+82.6%) | -$660.80 K(-9.4%) |
| Oct 2008 | - | -$131.90 K(-21.2%) | -$729.70 K(-25.1%) |
| July 2008 | - | -$167.40 K(+38.8%) | -$974.50 K(-18.2%) |
| Apr 2008 | -$1.19 M(+238.8%) | -$120.60 K(-61.1%) | -$1.19 M(-31.6%) |
| Jan 2008 | - | -$309.80 K(-17.8%) | -$1.74 M(+104.9%) |
| Oct 2007 | - | -$376.70 K(-1.9%) | -$849.70 K(+24.9%) |
| July 2007 | - | -$384.00 K(-42.7%) | -$680.20 K(+93.5%) |
| Apr 2007 | -$351.60 K(-67.2%) | -$670.30 K(-215.3%) | -$351.60 K(+671.1%) |
| Jan 2007 | - | $581.30 K(-380.6%) | -$45.60 K(-94.6%) |
| Oct 2006 | - | -$207.20 K(+274.0%) | -$849.10 K(+4.7%) |
| July 2006 | - | -$55.40 K(-84.8%) | -$810.60 K(-24.4%) |
| Apr 2006 | -$1.07 M(-61.7%) | -$364.30 K(+64.0%) | -$1.07 M(-18.2%) |
| Jan 2006 | - | -$222.20 K(+31.7%) | -$1.31 M(-14.5%) |
| Oct 2005 | - | -$168.70 K(-46.8%) | -$1.53 M(-39.5%) |
| July 2005 | - | -$317.00 K(-47.4%) | -$2.54 M(-9.4%) |
| Apr 2005 | -$2.80 M(+1165.9%) | -$602.90 K(+35.6%) | -$2.80 M(+20.0%) |
| Jan 2005 | - | -$444.60 K(-62.0%) | -$2.33 M(+19.7%) |
| Oct 2004 | - | -$1.17 M(+102.3%) | -$1.95 M(+146.8%) |
| July 2004 | - | -$578.90 K(+326.3%) | -$788.80 K(+256.9%) |
| Apr 2004 | -$221.00 K(+489.3%) | -$135.80 K(+123.7%) | -$221.00 K(+159.4%) |
| Jan 2004 | - | -$60.70 K(+353.0%) | -$85.20 K(+247.8%) |
| Oct 2003 | - | -$13.40 K(+20.7%) | -$24.50 K(+120.7%) |
| July 2003 | - | -$11.10 K | -$11.10 K |
| Apr 2003 | -$37.50 K(+70.5%) | - | - |
| Apr 2002 | -$22.00 K | - | - |
FAQ
- What is PharmaCyte Biotech annual cash flow from operations?
- What is the all time high annual CFO for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual CFO year-on-year change?
- What is PharmaCyte Biotech quarterly cash flow from operations?
- What is the all time high quarterly CFO for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly CFO year-on-year change?
- What is PharmaCyte Biotech TTM cash flow from operations?
- What is the all time high TTM CFO for PharmaCyte Biotech?
- What is PharmaCyte Biotech TTM CFO year-on-year change?
What is PharmaCyte Biotech annual cash flow from operations?
The current annual CFO of PMCB is -$2.15 M
What is the all time high annual CFO for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual cash flow from operations is -$22.00 K
What is PharmaCyte Biotech annual CFO year-on-year change?
Over the past year, PMCB annual cash flow from operations has changed by +$1.64 M (+43.29%)
What is PharmaCyte Biotech quarterly cash flow from operations?
The current quarterly CFO of PMCB is -$373.30 K
What is the all time high quarterly CFO for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly cash flow from operations is $581.30 K
What is PharmaCyte Biotech quarterly CFO year-on-year change?
Over the past year, PMCB quarterly cash flow from operations has changed by +$1.61 M (+81.19%)
What is PharmaCyte Biotech TTM cash flow from operations?
The current TTM CFO of PMCB is -$2.87 M
What is the all time high TTM CFO for PharmaCyte Biotech?
PharmaCyte Biotech all-time high TTM cash flow from operations is -$11.10 K
What is PharmaCyte Biotech TTM CFO year-on-year change?
Over the past year, PMCB TTM cash flow from operations has changed by -$396.30 K (-16.03%)